|
|
|
|
| LEADER |
05477nam a2200613 4500 |
| 001 |
ocn946104664 |
| 003 |
OCoLC |
| 005 |
20180501122030.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160408s2016 maua ob 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d N$T
|d YDXCP
|d EBLCP
|d OPELS
|d N$T
|d CDX
|d FDA
|d OCLCO
|d OCLCQ
|d VT2
|d CNCGM
|d OCLCQ
|e rda
|d MEU
|d GrThAP
|
| 019 |
|
|
|a 947222731
|
| 020 |
|
|
|a 0128040580
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128040584
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128040133
|
| 020 |
|
|
|a 0128040130
|
| 035 |
|
|
|a (OCoLC)946104664
|z (OCoLC)947222731
|
| 050 |
|
4 |
|a RC564
|b .A5588 2016eb
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.86/06
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Animal Models for Medications Screening to Treat Addiction /
|c edited by Richard L. Bell and Shafiqur Rahman.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (xix, 542 pages :
|b illustrations).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 126
|
| 546 |
|
|
|a Text in English.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed April 18, 2016).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Front Cover; Animal Models for Medications Screening to Treat Addiction; Copyright; Contents; Contributors; Preface; Chapter One: Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An ... ; 1. Predictive Validity; 2. Methodology; 3. Evaluating Selective Effects; 4. Nonhuman Primates; 5. Cue Effects and Reinstatement; 6. Conclusion; References; Chapter Two: A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective; 1. Introduction.
|
| 505 |
8 |
|
|a 2. The Need for Legislative Incentives for R & D of Dependence Medication2.1. Opiate Dependence and Treatment; 2.1.1. Methadone; 2.1.2. Vivitrol®; 2.1.3. Buprenorphine (Suboxone®); 2.2. Cocaine Dependence and Treatment; 2.3. Methamphetamine Dependence; 3. The Decline of R & D in Pharmaceutical Companies; 3.1. General Trends; 3.2. Reasons for Pharmaceutical Lack of R & D Into Drug Dependence Treatment; 4. Legislation Specifically Incentivizing R & D into Dependence Treatment; 4.1. Market Exclusivity; 4.2. Tax Credit; 4.3. Priority Review Vouchers; 4.4. Advanced Market Commitment.
|
| 505 |
8 |
|
|a 4.5. Liability Reduction4.6. Political Considerations; 5. Conclusion; References; Chapter Three: Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking; 1. Methamphetamine Actions and Abuse; 2. Overview of Existing MA Medications Studies; 2.1. Dopamine; 2.2. Vesicular Monoamine Transporter 2; 2.3. Gamma-Aminobutyric Acid; 2.4. Cyclic AMP; 2.5. Replacement Therapy and Treating Withdrawal; 2.6. Immunotherapy and Neuroimmune Therapy; 3. Support for the Importance of Genetic Factors in Human Risk for MA Abuse; 3.1. Brain-Derived Neurotrophic Factor.
|
| 505 |
8 |
|
|a 3.2. Dopamine Beta-Hydroxylase3.3. Catechol-O-Methyltransferase; 3.4. Fatty Acid Amide Hydrolase; 3.5. Mu Opioid Receptor; 3.6. Monoamine Oxidase A; 4. Development of Selectively Bred Lines for High and Low MA Intake; 4.1. Existing Behavioral and Physiological Data for the MA Drinking Lines; 4.1.1. Nondrug-Related Behavioral Traits; 4.1.2. Drug Reward-Related Traits; 4.1.3. Drug Aversion-Related Traits; 4.1.4. Locomotor Activation and Sensitization; 4.1.5. Impulsivity; 4.1.6. Circadian Period; 4.1.7. Body Temperature; 4.2. Blood Drug Levels; 4.3. Neurochemical Information.
|
| 505 |
8 |
|
|a 4.4. Genetic Findings and Treatment5. Speculation About Mechanisms and Treatment Targets; Acknowledgments; References; Chapter Four: Screening Medications for the Treatment of Cannabis Use Disorder; 1. Introduction; 2. Animal Models; 3. Findings from Research with Animal Models; 4. Human Laboratory Approaches; 5. Findings from Clinical Trials and Laboratory Studies in Human Volunteers; 6. Conclusion; Acknowledgments; References; Chapter Five: How can we Improve on Modeling Nicotine Addiction to Develop Better Smoking Cessation Treatments?; 1. Introduction; 2. Animal Models.
|
| 520 |
8 |
|
|a Annotation
|b This volume brings together information on the current state of medication development for drug addiction using animal models. It contains comprehensive descriptions of various models associated with many forms of drug addiction.
|
| 650 |
|
0 |
|a Substance abuse
|x Treatment
|x Animal models.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Bell, Richard L.,
|d 1961-
|e editor.
|
| 700 |
1 |
|
|a Rahman, Shafiqur,
|d 1963-
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Bell, Richard L.
|t Animal Models for Medications Screening to Treat Addiction.
|d : Elsevier Science, ©2016
|z 9780128040133
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 126.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00747742/126
|z Full Text via HEAL-Link
|
